GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exelixis Inc (NAS:EXEL) » Definitions » Price-to-Free-Cash-Flow

Exelixis (Exelixis) Price-to-Free-Cash-Flow

: 43.00 (As of Today)
View and export this data going back to 2000. Start your Free Trial

As of today (2024-04-18), Exelixis's share price is $22.49. Exelixis's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.52. Hence, Exelixis's Price-to-Free-Cash-Flow Ratio for today is 43.00.

The historical rank and industry rank for Exelixis's Price-to-Free-Cash-Flow or its related term are showing as below:

EXEL' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 9.28   Med: 25.48   Max: 68.15
Current: 43

During the past 13 years, Exelixis's highest Price-to-Free-Cash-Flow Ratio was 68.15. The lowest was 9.28. And the median was 25.48.

EXEL's Price-to-Free-Cash-Flow is ranked worse than
59.05% of 210 companies
in the Biotechnology industry
Industry Median: 30.53 vs EXEL: 43.00

Exelixis's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-0.01. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $0.52.

During the past 12 months, the average Free Cash Flow per Share Growth Rate of Exelixis was -23.30% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was -1.90% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -16.10% per year.

During the past 13 years, Exelixis's highest 3-Year average Free Cash Flow per Share Growth Rate was 40.10% per year. The lowest was -73.30% per year. And the median was -1.90% per year.


Exelixis Price-to-Free-Cash-Flow Historical Data

The historical data trend for Exelixis's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exelixis Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.80 35.71 17.51 23.21 45.26

Exelixis Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Free-Cash-Flow Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.21 53.47 29.31 53.03 45.26

Competitive Comparison

For the Biotechnology subindustry, Exelixis's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Exelixis Price-to-Free-Cash-Flow Distribution

For the Biotechnology industry and Healthcare sector, Exelixis's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Exelixis's Price-to-Free-Cash-Flow falls into.



Exelixis Price-to-Free-Cash-Flow Calculation

Exelixis's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=22.49/0.523
=43.00

Exelixis's Share Price of today is $22.49.
Exelixis's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.52.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Exelixis  (NAS:EXEL) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Exelixis Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Exelixis's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Exelixis (Exelixis) Business Description

Traded in Other Exchanges
Address
1851 Harbor Bay Parkway, Alameda, CA, USA, 94502
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Executives
Patrick J. Haley officer: Sr. Vice President, Commercial 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Jeffrey Hessekiel officer: EVP and General Counsel 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
David Edward Johnson director 590 MADISON AVENUE, NEW YORK NY 10022
Dana Aftab officer: CSO/EVP Disc & Trans Research EXELIXIS, INC., 1851 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Amy C. Peterson officer: EVP Prod Dev & Med Aff & CMO C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
Christopher J. Senner officer: EVP and CFO 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Tomas J. Heyman director C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080
Bob Oliver director C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Caligan Partners Lp director, other: See Remarks 515 MADISON AVENUE, 8TH FLOOR, NEW YORK NY 10022
Jack L Wyszomierski director SCHERING PLOUGH CORP, ONE GIRALDA FARMS, MADISON NJ 07940-1000
Alan M Garber director 3355 MILTON COURT, MOUNTAIN VIEW CA 94040
Carl B Feldbaum director C/O EXELIXIS INC, 170 HARBOR WAY, PO BOX 511, SOUTH SAN FRISCISCO CA 94083-0511
Peter Lamb officer: EVP, Discovery Research & CSO PO BOX 511, 170 HARBOR WAY, SOUTH SAN FRANCISCO CA 94083-0511
George Poste director 515 GALVESTON DR, REDWOOD CITY CA 94063
Lance Willsey director C/O EXELIXIS INC, 170 HARBOR WAY, SAN FRANCISCO CA 94083

Exelixis (Exelixis) Headlines

From GuruFocus

Exelixis Announces $550 Million Share Repurchase Program

By Business Wire Business Wire 03-20-2023